Despite the excessive hopes for the brand new assessments, there are a lot of questions.
Some critics say {that a} deal with treating youthful folks is misplaced as a result of they might not adjust to taking a statin or one other drug for the remainder of their lives. It may be troublesome for younger folks to deal with potential threats to their well being many years sooner or later, and a few of Dr. Rader’s sufferers have delay even getting polygenic danger assessments after he recommends them.
The actual want, these critics say, is with the large group of older individuals who want cholesterol-lowering therapy however will not be getting it, or who’re abandoning their prescriptions. In one examine, about 40 p.c of individuals 65 and older who had a coronary heart assault and want lipid-lowering drugs for the remainder of their lives cease taking statins inside two years.
Others, like Dr. Rita F. Redberg, a heart specialist on the University of California, San Francisco, the editor at JAMA Internal Medicine and a critic of the overuse of statins, is worried that polygenic danger scores may introduce new issues.
“There is a lot of downside to labeling people with a disease,” she stated.
The label, she added, “inexorably leads to tests and a search for treatments.” And, she stated, “because the person, who now has become a ‘patient,’ is asymptomatic, more tests and possible treatments in most cases will not make the person feel any better.”
People can go from considering of themselves as wholesome to considering of themselves as somebody with a illness. “Now, whenever they experience the common aches, pains and twinges of life, they wonder if it is because they have this ‘disease,’” Dr. Redberg stated. “And they may then go to the doctor or even emergency room for things they would not have previously. And that also will lead to more tests and procedures, with their attendant risk of harms.”